WuXi STA tapped as preferred partner for Beta Pharma

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Pinkypills)
(Image: Getty/Pinkypills)

Related tags WuXi STA

WuXi STA becomes the preferred CDMO partner for Beta Pharma as the company launches a Phase II clinical trial in China and begins preclinical research for an additional target.

STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, will use the Marketing Authorization Holder (MAH) scheme to advance Beta Pharma’s late phase and commercial targets.

The MAH scheme, first piloted in 2017​, enables drug license holders to use a third party manufacturer instead of building GMP manufacturing capabilities in-house, as was previously required in China.

Read: Chinese R&D sector takes ‘significant step’ as outsourcing demand increases

Headquartered in Princeton, NJ, Beta Pharma is a biotech company focusing on oncology drug discovery and development.

Under the terms of the collaboration, the contract development and manufacturing organization (CDMO) WuXi STA will become the preferred partner for Beta Pharma, which in February 2019 launched​ a Phase II clinical trial in China for the target BPI-7711.

According to the company, BPI-7711 is a third generation of EGFR TKI and aims to treat mutation positive non-small cell lung cancer.

Beta Pharma also is in the preclinical research phase with another target, BPI-1178, for the treatment of metastatic breast cancer. It expects to submit a clinical application in the first quarter of 2019.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more